Physicians' Academy for Cardiovascular Education

Triglycerides

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD

MI risk is best captured by number of apoB-containing lipoproteins

5' education - Apr. 20, 2022 - Nicolas Marston, MD

Residual CV risk in patients on statin therapy

10' education - Apr. 13, 2022 - Prof. Alberto Zambon, MD, PhD

Targeting triglyceride-rich remnant lipoproteins

10' education - Dec. 21, 2021 - Prof. Daniel Gaudet, MD, PhD

Why focus on triglyceride-rich lipoproteins and their remnants?

10' education - Nov. 23, 2021 - Prof. Henry Ginsberg, MD

Integrating EPA-based therapy in the management of residual CV risk

10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Online CME

Triglyceride-rich lipoproteins and residual CV risk

10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD - Online CME

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD - Online CME

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD

Results of omega-3 fatty acids trials may not be contradictory

3' education - Nov. 16, 2020 - Prof. Deepak Bhatt, MD

No effect of omega-3 carboxylic acid on MACE in high-risk patients

3' education - Nov. 16, 2020 - Prof. Michael Lincoff, MD

Lessons from REDUCE-IT

10' education - Nov. 12, 2020 - Prof. Deepak Bhatt, MD - Online CME

Latest results with non-LDL lowering agents in reducing CV risk

10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD

Non-LDL-c parameters in CV risk management and guidelines

10' education - Oct. 13, 2020 - Prof. Kausik Ray, MD - Online CME

Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia

10' education - Sep. 29, 2020 - Prof. François Mach, MD

The residual risk challenge in CVD: How important are triglycerides?

10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD

A marriage of clinical trial results and imaging findings with icosapent ethyl

10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD

Burden of residual risk: Are triglycerides a risk marker?

10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD

Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia

3' education - May 25, 2020 - Benjamin Peterson, MD

Mechanistic underpinning of CV benefit observed with icosapent ethyl

3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Three lines of evidence for triglycerides as a CV risk factor

10' education - Dec. 17, 2019 - Prof. Ph. Gabriel Steg

Possible favorable effects of icosapent ethyl on plaque-parameters

3' education - Nov. 25, 2019 - Prof. Stephen Nicholls - AHA 2019, Philadelphia

Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk

3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD

Childhood risk factors associated with CV events in adulthood

Literature - Apr. 26, 2022 - Jacobs, Jr. DE et al. - N Engl J Med. 2022

A study demonstrated that traditional CV factors (BMI, SBP, total cholesterol level, triglyceride level, and smoking) in childhood are associated with CV events during adulthood.

Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl

10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD
Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.

Exploring the role of icosapent ethyl based on current clinical evidence

10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT.

What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.

MI risk is best captured by number of apoB-containing lipoproteins

5' education - Apr. 20, 2022 - Nicolas Marston, MD
Does the type or lipid content of apoB-containing lipoprotein carry any additional risk of MI beyond the total number of apoB-containing lipoproteins?

Does the type or lipid content of apoB-containing lipoprotein carry any additional risk of MI beyond the total number of apoB-containing lipoproteins?

Residual CV risk in patients on statin therapy

10' education - Apr. 13, 2022 - Prof. Alberto Zambon, MD, PhD
Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in  patients who are already being treated with statins.

Prof. Zambon talks about established and emerging risk factors that may contribute to residual CV risk in patients who are already being treated with statins.

Phase 3 CV outcomes study with pemafibrate stopped early

News - Apr. 11, 2022

The PROMINENT study, which investigated whether pemafibrate could reduce CV outcomes by reducing triglycerides in patients with T2DM, will be stopped early.

Modest effect on apoB and key safety findings with ASO targeting ANGPTL3 mRNA

News - Apr. 3, 2022

ACC 2022 Treatment with vupanorsen, the antisense oligonucleotide (ASO) targeting ANGPTL3 mRNA, resulted in reduced non-HDL-c and TG levels at all doses, but apoB was modestly reduced. Importantly, there were key safety and tolerability findings with vupanorsen.

ApoB is the only independent driver of lipid-associated MI risk

Literature - Mar. 15, 2022 - Marston NA, et al. - JAMA Cardiol 2022

In a cohort study, number of apoB-containing lipoprotein captures risk of myocardial infarction best, and this association is independent from lipid content (cholesterol or TG) or type (LDL or TG-rich) of lipoprotein.

Clinically relevant differences in LDL-c levels estimated by three different equations

Literature - Feb. 23, 2022 - Sajja A et al. - J Am Coll Cardiol. 2022

A study found clinically meaningful differences in LDL-c values estimated by the Friedewald, Sampson, and Martin/Hopkins equations, especially in patients with TG levels ≥150 mg/dL and at lower LDL-c values.

ApoC-III inhibition reduces triglycerides in patients at high risk for or with established ASCVD

Literature - Jan. 31, 2022 - Tardif JC et al. - Eur Heart J. 2022

Olezarsen is a (GalNAc)-conjugated, antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apoC-III. This phase 2 study investigated the effect of apoC-III inhibition by olezarsen on triglyceride levels.

Targeting triglyceride-rich remnant lipoproteins

10' education - Dec. 21, 2021 - Prof. Daniel Gaudet, MD, PhD
Prof. Daniel Gaudet gives an overview of emerging therapies targeting triglyceride-rich remnant lipoproteins.

Prof. Daniel Gaudet gives an overview of emerging therapies targeting triglyceride-rich remnant lipoproteins. With question to test your knowledge.

Phase 2b trial evaluating ANGPTL3 antisense meets primary endpoint

News - Nov. 29, 2021

The TRANSLATE-TIMI 70 trial, a dose-ranging phase 2b study with the ANGPTL3 antisense vupanorsen in subjects with dyslipidemia, met its primary endpoint: a significant reduction of non-HDL-c at 24 weeks with vupanorsen compared to placebo.